The 2024 American Diabetes Association guidelines on Standards of Medical Care in Diabetes: key takeaways for laboratory
Dipti Tiwari , Tar Choon Aw
Exploration of Endocrine and Metabolic Diseases ›› 2024, Vol. 1 ›› Issue (4) : 158 -66.
The escalating prevalence of diabetes poses a significant health concern. Uncontrolled diabetes leads to a multitude of complications. A comprehensive management plan and continual adaptation of guidelines is needed. The American Diabetes Association (ADA) is a guiding force in this domain, providing diabetes care recommendations for clinicians, laboratorians, researchers, and policymakers since 1989. The latest ADA guidelines present both challenges and opportunities for laboratories. The increased emphasis on glycated hemoglobin (HbA1c) testing for early diagnosis and personalized monitoring is expected to increase testing volumes, potentially leading to a rise in point-of-care testing. Ensuring standardized testing procedures becomes paramount to maintaining consistent and reliable results across laboratories. Moreover, laboratories may need to expand their test menus to accommodate the growing demand for personalized medicine approaches and collaborate closely with healthcare providers to support informed decision-making. This commentary provides a focused analysis of the 2024 ADA guidelines for the laboratory assessment of diabetes.
American Diabetes Association 2024 guidelines / cardiovascular-kidney-metabolic health / continuous glucose monitoring / diabetes / diabetic kidney disease
| [1] |
IDF Diabetes Atlas Reports [Internet]. International Diabetes Federation; c2022 [cited 2023 Dec 20]. Available from: https://diabetesatlas.org |
| [2] |
|
| [3] |
American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S20-42. |
| [4] |
American Diabetes Association Professional Practice Committee. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S111-25. |
| [5] |
Franceschi R. Precision Medicine in Diabetes, Current Research and Future Perspectives. J Pers Med. 2022; 12: 1233. |
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Kovács G, Nagy D, Szilberhorn L, Zelei T, Gaál Z, Vellekoop H, |
| [14] |
American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S179-218. |
| [15] |
|
| [16] |
Palazzuoli A, Iacoviello M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail Rev. 2023; 28: 585-96. |
| [17] |
|
| [18] |
|
| [19] |
American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S219-30. |
| [20] |
|
| [21] |
|
| [22] |
American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S145-57. |
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
American Diabetes Association Professional Practice Committee. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S282-94. |
| [27] |
|
| [28] |
|
| [29] |
American Diabetes Association Professional Practice Committee. 7. Diabetes Technology: Standards of Care in Diabetes-2024 . Diabetes Care. 2024; 47: S126-44. |
| [30] |
|
/
| 〈 |
|
〉 |